

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978

Status	RECRUITING
Phase	Phase 1
Sponsor	Fate Therapeutics
Enrollment	244 participants

Key Eligibility Criteria

Inclusion (5)

- Age: 12 to 70 years old.
- Diagnosis: Must have active B-cell mediated autoimmune disease (SLE, AAV, IIM, or SSc) confirmed by standard criteria.
- Disease Severity: Moderate to severe, requiring at least two prior treatments that were ineffective.
- Health Status: Adequate organ function to tolerate treatment.
- Consent: Able to provide informed consent or assent/obtain parental consent and comply with study procedures.

Exclusion (6)

- Pregnancy/Breastfeeding: Women must not be pregnant or nursing.
- Severe Organ Dysfunction: Significant heart, lung, liver, or kidney impairment.
- Active Infections: No recent or ongoing serious infections.
- Recent Cancer or Prior Cell Therapy: No active/recent malignancies, prior CAR T-cell therapy, or organ transplant.
- Allergies: No known allergies to study treatments.

... and 1 more (see full listing online)

Locations (17 total)

Providence Medical Foundation, Fullerton, California, United States
University of California Irvine, Irvine, California, United States
Children's Hospital Los Angeles Division Of Rheumatology, Los Angeles, California, United States
... and 14 more locations